+2 More
Schrödinger, Inc. is a global science and technology company specializing in computational chemistry, artificial intelligence, and molecular simulation. Founded in 1990 and headquartered in New York City, the company operates offices across the United States, Europe, and Asia. Schrödinger develops an integrated computational platform that combines physics-based modeling with machine learning to accelerate innovation in drug discovery and materials science. Its overarching goal is to enhance human health and quality of life by delivering highly accurate in silico predictions for therapeutic and industrial material design.
Schrödinger’s mission is to accelerate scientific innovation through digital chemistry approaches in molecular and materials design. With over 900 employees and more than three decades of research and development experience, the company is a leader in computational science. Its executive and scientific leadership teams include experts in chemistry, biology, artificial intelligence, and computational physics. The company’s sustainability strategy, known as VALUE², emphasizes environmental responsibility, diversity, and ethical technology practices.
The Schrödinger Platform is a modular software ecosystem integrating physics-based molecular modeling with modern machine learning techniques. It supports a wide range of applications—from small-molecule drug design and protein engineering to biomolecular modeling and advanced materials development.
Key products include:
Schrödinger’s software suite is used across multiple scientific and industrial domains:
By integrating experimental and computational data into a single digital framework, Schrödinger enables fully digital design–build–test–analyze cycles in research and development.
Schrödinger maintains strategic collaborations with major technology and pharmaceutical companies. Notably, it partners with NVIDIA to optimize GPU-based high-performance computing for molecular simulations. Its software has been applied in drug discovery programs with companies such as AbbVie, Takeda, Galapagos, and Morphic Therapeutic, where computational insights have guided the design of clinical candidates, including TYK2 and MALT1 inhibitors.
The company integrates sustainability and ethical responsibility into its corporate policies. Efforts include LEED-compliant workspaces, reduced energy consumption, carbon footprint monitoring, and efficient use of scientific resources. Schrödinger also engages in collaborative global health programs focused on early-stage discovery for diseases such as malaria, tuberculosis, and non-hormonal contraceptives.
Through the integration of physics-based modeling and artificial intelligence, Schrödinger expands the frontiers of computational design in both modern drug discovery and materials development. Its platform accelerates decision-making by merging experimental and computational insights, thereby enhancing design precision and efficiency in the molecular sciences.
Corporate Structure and Mission
Technology Platform and Product Portfolio
Applications
Collaborations and Research Network
Sustainability and Social Impact
Vision
This article was created with the support of artificial intelligence.